Table 8. Summary of patient characteristics, mutation types, and allele burdens in patients with both JAK2 and CALR mutations in this study and previous studies.

No. Case	Diagnosis	Sex	Age	CALR mutation	CALR allele burden (%)	JAK2 allele burden (%)	Reference
1	ET	U	U	U	U	U	[4]
2	RARS-T	F	73	c.1129_1138del	U	4	[5]
3	PMF	U	U	c.1092_1143del (type 1)	U	U	[6]
4	ET	F	79	c.1094_1139del (type 6)	10.5	<1	[7]
5–8	PMF	U	U	U	U	U	[8]
9	ET	U	U	c.1092_1143del (type 1)	U	0.03	[9]
10	ET	F	62	c.1095_1140del (type 3)	24.22	0.16	this study
11	ET	M	29	c.1144del	50.37	0.27	this study
12	ET	F	71	c.1092_1143del (type 1)	61.08	0.12	this study
13	ET	F	61	U*	4.47	0.10	this study
14	ET	F	74	c.1092_1143del (type 1)	89.48	0.38	this study
15	ET	M	37	c.1092_1143del (type 1)	40.65	0.14	this study
16	ET	M	57	c.1154_1155insTTGTC (type 2)	36.92	0.26	this study
17	ET	F	77	c.1092_1143del (type 1)	47.54	0.28	this study

ET, essential thrombocythemia; RARS-T, refractory anemia with ringed sideroblasts and marked thrombocytosis; PMF, primary myelofibrosis; U, unknown; F, female; M, male.

^*CALR mutations were detected only via gene fragment analysis owing to low allele burden.